The treatment of mCRC is based on the combination of polychemotherapy schemes based on oxaliplatin and/or irinotecan associated with biological agents, such as anti-EGFR or antiangiogenic agents, depending on parameters such as the mutational status of RAS and BRAF or tumor sidedness [3]. The gene discussed is BRAF; the disease is neoplasm.